Drug Trial Radar · NCT01074294
Study of the Safety and Efficacy of OPC-34712 as a Complementary Therapy in the Treatment of Adult Attention Deficit/Hyperactivity Disorder
Last checked: Nov 19, 2026Latest source record: Feb 2, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
740
Actual
Start
Mar 16, 2010
Primary completion
Jun 20, 2011
Study completion Jun 20, 2011
Sponsor
- Lead sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.Otsuka
- Sponsor type
- Industry
- First posted
- Feb 24, 2010
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 55 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study tests the effects of an investigational antipsychotic drug (called OPC-34712) in adults with attention deficit hyperactivity disorder (ADHD) when taken with an approved stimulant medication to explore a possible impact on sleep, quality of life and cognitive function.
Conditions
- Attention Deficit Hyperactivity Disorder
Interventions
OPDC-34712Drug
OPDC-34712 tablets, daily, Orally.
PlaceboDrug
Matching-placebo tablets, daily, Orally.
Stimulant TherapyDrug
Mixed amphetamine salts or Dexmethylphenidate hydrochloride (HCL) or Methylphenidate HCl or Lisdexamfetamine dimesylate as per standard of care.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Mean Change From Baseline (End of Phase A) in the CAARS-O:SV ADHD Symptoms Total Score (18 Items) to End of Phase BTime frame: Baseline [end of Phase A (Week 5)] to Week 11
Locations
35 sites in 1 country. Site status is shown where the registry gives one.
Site not named
Little Rock, Arkansas
Site not named
Beverly Hills, California
Site not named
Irvine, California
Site not named
Pasadena, California
Site not named
San Francisco, California
Site not named
Bradenton, Florida
Site not named
Jacksonville, Florida
Site not named
Maitland, Florida
Site not named
North Miami, Florida
Site not named
Orlando, Florida
Site not named
South Miami, Florida
Site not named
Atlanta, Georgia
Site not named
Smyrna, Georgia
Site not named
Indianapolis, Indiana
Site not named
Overland Park, Kansas
Site not named
Rochester Hills, Michigan
Site not named
Saint Charles, Missouri
Site not named
Cherry Hill, New Jersey
Site not named
Willingboro, New Jersey
Site not named
New York, New York
Site not named
Chapel Hill, North Carolina
Site not named
Durham, North Carolina
Site not named
Cincinnati, Ohio
Site not named
Dayton, Ohio
Site not named
Oklahoma City, Oklahoma
Site not named
Portland, Oregon
Site not named
Philadelphia, Pennsylvania
Site not named
Memphis, Tennessee
Site not named
Austin, Texas
Site not named
Houston, Texas
Site not named
Salt Lake City, Utah
Site not named
Woodstock, Vermont
Site not named
Herndon, Virginia
Site not named
Bellevue, Washington
Site not named
Seattle, Washington
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.